{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.9","upperLimit":"10.8","value":"7.7"},{"groupId":"OG001","lowerLimit":"3.7","upperLimit":"12.7","value":"8.7"},{"groupId":"OG002","lowerLimit":"3.8","upperLimit":"22.5","value":"12.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"54"},{"groupId":"OG002","value":"45"}],"units":"Participants"}],"description":"Duration of Response was defined as the duration of overall response measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started). Per planned analysis, duration of response by local assessment was assessed for TNBC Target Population, HR+/HER2-mBC Population, and mUC Population.","dispersionType":"95% Confidence Interval","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"},{"description":"Overall 68 participants with non-TNBC were enrolled in the study and received at least one dose of SG. Of these 68 participants, 54 were confirmed as HR+/HER2-, had progressed on at least one prior hormonal therapy in the metastatic setting, and had received at least one dose of 10 mg/kg SG. These 54 participants were included in the analysis of safety and were referred to as the HR+/HER2- mBC Population.","id":"OG001","title":"HR+/HER2- mBC Population"},{"description":"Overall 49 participants with metastatic urothelial cancer were enrolled in the study and received at least one dose of SG. Of these 49 participants, 45 had either relapsed after or were refractory to at least one prior standard therapeutic regimen and received at least one dose of 10 mg/kg SG. These 45 participants were included in the analysis of safety and were referred to as the mUC Population.","id":"OG002","title":"mUC Population"}],"paramType":"MEDIAN","populationDescription":"* Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease \\& who received at least 1 dose of 10 mg/kg SG\n* HR+/HER2-mBC: Participants with HR+/HER2- mBC who progressed on at least 1 prior hormonal therapy \\& who received at least 1 dose of 10 mg/kg SG\n* mUC: Participants who had relapsed after or were refractory to at least 1 prior treatments \\& who received at least 1 dose of 10 mg/kg SG","reportingStatus":"POSTED","timeFrame":"Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)","title":"Duration of Response by Local Assessment","type":"SECONDARY","unitOfMeasure":"months"}